Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis: MAGNIFY-MS

BACKGROUND AND OBJECTIVES: The onset of action for high-efficacy immunotherapies in multiple sclerosis (MS) is an important parameter. This study (MAGNIFY-MS) evaluates the onset of action of cladribine tablets by observing changes in combined unique active (CUA) MRI lesion counts during the first 6...

Descripción completa

Detalles Bibliográficos
Autores principales: de Stefano, Nicola, Barkhof, Frederik, Montalban, Xavier, Achiron, Anat, Derfuss, Tobias, Chan, Andrew, Hodgkinson, Suzanne, Prat, Alexandre, Leocani, Letizia, Schmierer, Klaus, Sellebjerg, Finn, Vermersch, Patrick, Wiendl, Heinz, Keller, Birgit, Roy, Sanjeev
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
RESEARCH Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197134/
https://www.ncbi.nlm.nih.gov/pubmed/35701185
http://dx.doi.org/10.1212/NXI.0000000000001187

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197134/
https://www.ncbi.nlm.nih.gov/pubmed/35701185
http://dx.doi.org/10.1212/NXI.0000000000001187

Ejemplares similares